Core Viewpoint - Defiance ETFs has launched the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ), which provides investors with 2X inverse daily exposure to the performance of Eli Lilly and Company, allowing retail investors to seek enhanced downside exposure without needing a margin account [1][3]. Group 1: Fund Overview - LLYZ aims to deliver daily investment results of -200% of the daily performance of Eli Lilly and Company, utilizing derivatives such as swaps and options to achieve its leveraged objectives [2]. - The fund is designed for knowledgeable investors who understand the risks associated with seeking daily leveraged inverse investment results and are willing to actively monitor their portfolios [4]. Group 2: Company Profile - Eli Lilly and Company is recognized as a global leader in the pharmaceutical industry, known for its innovative therapies in areas such as diabetes, oncology, immunology, and neuroscience [3]. - The fund offers targeted inverse exposure for traders looking for amplified downside exposure without the need for a margin account, distinguishing it from direct investments in Eli Lilly [3]. Group 3: Company Background - Defiance, founded in 2018, specializes in thematic, income, and leveraged ETFs, positioning itself as a leader in ETF innovation [5]. - The company focuses on empowering investors to take amplified positions in high-growth companies through its first-mover leveraged single-stock ETFs [5].